Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Half of women treated for gynecologic cancers miss or skip doses of oral drugs
Key clinical point: Clinicians may be overlooking imperfect adherence to oral anticancer drugs for gynecologic cancers.
Major finding: More than half of women taking oral anticancer agents for ovarian or uterine cancer miss or skip doses.
Study details: A cross-sectional questionnaire study enrolling 100 women treated with oral anticancer agents at a single treatment center.
Disclosures: Dr. Watson and colleagues’ study was supported by their institution. One coauthor reported financial ties with drug manufacturers in the form of grant and clinical trial support and honoraria. Another coauthor is the member of various boards and steering committees, which are uncompensated.
Watson C et al. Obstet Gynecol. 2020. doi: 10.1097/AOG.0000000000004170.